Corrigendum to the Annual Report for the FY 2025-26

FISCHER MEDICAL VENTURES LIMITED (Formerly known as Fischer Chemic Limited) Registered Office Address: Survey No. 480/2 AP Medtech Zone, Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032 CIN: L86900AP1993PLC118162 Email: cs@fischermv.com | Website: www.fischermv.com | Contact 9080966548 September 26 2026 To To National Stock Exchange of India Ltd. Exchange BSE Limited Plaza, 5tll floor Corporate Relationship Department Plot No. C/ 1, G Block, 25th Floor, P J Towers Bandra-Kurla Complex Bandra (E), Dalal Street, Fort, Mumbai - 400 051 Mumbai – 400 001 NSE Symbol: FISCHER BSE Scrip Code: 524743 Dear Sir/ Madam, The Annual Report of the Company along with the Notice for the 33rd Annual General Meeting of Fischer Medical Ventures Limited was emailed/despatched to the shareholders and other stakeholders of the Company on 7th September 2026. This corrigendum is being issued to update certain inadvertent errors/omissions that occurred in the Annual Report of the Company for the financial year 2025-26. The necessary corrections as listed below: (revised Annual Report is attached herewith) Page No. 70, In Financial Highlights and Key Financial Ratios minor errors are corrected. Page No. 136 and 182, Independent Standalone and Consolidated Auditor’s Report, the UDIN is corrected. Page No. 147 and 193, Paid up Equity Share Capital is corrected in the Standalone and Consolidated Profit and Loss Statement. Page No. 171, Notes to Standalone Financials- Note No. 32 Financial Risk Management Objectives and Policies- Maturity Analysis of Assets and Liabilities table is revised for presentation purposes. Page No. 173, Notes to Standalone Financials- Note No. 32 Financial Risk Management Objectives and Policies- Prior year numbers are corrected in the Capital Management table. Page No. 220 Note No. 39, Foreign Currency Exposure table is updated. Page No. 222 Note No. 39, Maturity Analysis of Financial Assets and liabilities table is updated. In view of the aforesaid, we are submitting the updated Annual Report of the Company for FY 2025-26 after incorporating the aforesaid changes. We request you to kindly take note of the same. Thanking you, For Fischer Medical Ventures Limited BALAJI GANDLA COMPANY SECRETARY AND COMPLIANCE OFFICER Corporate Office: Level 8, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai, Tamil Nadu, 600006 NEXT PHASE OF What's Inside INNOVATION LED GROWTH 01-47 48-135 136-232 CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS Innovation has never been a one-time achievement Now, we are entering the Next Phase of Innovation-Led for us. It has been our way of thinking, building and Growth. 01 Next Phase of Innovation Led 48 Board's Report Standalone Financial Statements growing. Every milestone we have achieved has Growth 59 Management Discussion and 136 Independent Auditor's Report For us, this next phase is about scaling what we have built. reinforced our belief that indigenous healthcare 02 Who we Are Analysis 147 Balance Sheet It means expanding the reach of our imaging portfolio, technology can transform lives while making quality 06 Our Corporate Journey and 72 Business Responsibility and 149 Statement of Profit and Loss accelerating our pipeline of breakthrough healthcare Milestone Sustainability Report care more accessible and affordable. 150 Cash Flow Statement technologies, expanding into other segments, 08 Message from the Chairman’s 106 Corporate Governance Report Last year, we demonstrated the strength of that strengthening our manufacturing capabilities, and taking Desk 152 Statement of Changes in Equity belief. We crossed ₹100 crore in consolidated revenue, the Fischer name to newer markets across India and 12 Chief Operating Officers 153 Notes to Financial Statements Communique Consolidated Financial Statement earned the trust of leading radiologists through our beyond. 16 Our Offerings MRI platforms, and showcased our capabilities on While our ambitions are growing, our purpose remains 182 Independent Auditor's Report global platforms. These achievements were not an 20 Operating Environment unchanged. Every innovation we pursue is driven by a single 193 Balance Sheet end in themselves—they gave us the confidence to 24 Technological Imperatives conviction—to make advanced, preventive and technology- 195 Statement of Profit and Loss think bigger. 28 Strategic Overview led healthcare more accessible to millions. 196 Cash Flow Statement 32 Our Leadership Team 198 Statement of Changes in Equity 33 Board of Directors We decoded healthcare. 199 Notes to Financial Statements 36 Our Senior Management Now, we are scaling it. 40 Human Resource 233 NOTICE OF THE AGM 42 Financial Highlights This is our Next Phase of Innovation-Led Growth. 44 Governance 46 Risk Management and Analysis 47 Corporate Information INVESTOR INFORMATION Market Capitalisation as at March 31st, 2026 2,644.89 Cr L86900AP1993PLC118162 BSE Code Scan the QR 524743 code to view our Annual Report NSE Code FISCHER AGM Date Please find our online version at: September 29th, 2026 https://fischermv.com/ir/ AGM Venue Online/VC Disclaimer This Annual Report contains statements that may be regarded as forward-looking in nature, reflecting Fischer Medical Ventures Limited expectations, projections, estimates, and assumptions regarding future events, business performance, and financial outcomes. Such statements are based on current views and assumptions and are inherently subject to various risks, uncertainties, and other factors that may cause actual results to differ materially from those anticipated. Readers are advised not to place undue reliance on these forward-looking statements, as several factors—including economic conditions, market developments, regulatory changes, competitive dynamics, and other unforeseen circumstances—could influence actual outcomes. Our Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Corporate Overview Statutory Report Standalone Financial Statements Consolidated Financial Statements Notice Who we are OUR VISION TRANSFORMING HEALTHCARE To be the world’s leading healthcare technology partner, pioneering the ABC of Healthcare — AI, THROUGH INNOVATION Big Data, and computing — to empower providers, enhance patient care, and revolutionise the future of medicine through Innovation, Inclusion, and Impact. ₹308.58 Consolidated Revenue — 2025-26 OUR MISSION To transform global healthcare through innovative, ₹55.40 accessible, and affordable medical technologies spanning imaging, diagnostics, and preventive care — EBITDA — 2025-26 while leveraging digital health, AI, and data analytics to improve patient outcomes and optimise healthcare delivery. ₹31.07 Net Profit — 2025-26 OUR VALUES Innovation with Purpose ₹671 We drive technological advancement to solve real Consolidated Total Assets — 2025-26 world healthcare challenges and improve lives across diverse populations. $7 Affordability and Accessibility Mn + New Government Orders — 2025-26 We believe everyone deserves access to world-class healthcare and are committed to delivering high- quality solutions at sustainable costs. Multiple Platforms Integrity and Transparency 4+ New Product & Regulatory We operate with the highest ethical standards, Milestones — 2025-26 fostering trust with our patients, partners, investors, and communities. Fischer Medical Ventures Limited (hereafter of indigenously developed MRI systems, supported Global Impact, Local Focus referred to as “FMVL”, “Our Company” or “We”) is a by our state-of-the-art manufacturing facility at Vizag-headquartered medical technology company the Andhra Pradesh MedTech Zone (AMTZ), we are While we innovate for the world, we stay grounded delivering an integrated healthcare ecosystem advancing indigenous MedTech capabilities through in addressing the specific healthcare needs of spanning magnetic resonance imaging [Showing first 8,000 characters — download PDF for full document]